Regeneron Pharmaceuticals, Inc. officer Andrew J. Murphy filed a Form 144 notice on November 17, 2026, disclosing a proposed sale of 5,011 shares of common stock through UBS Financial Services, Inc. on Nasdaq.
Key Highlights
- Proposed sale: 5,011 shares of Regeneron common stock, with an aggregate market value of $4,773,278.16, according to the filing.
- Acquisition method: The 5,011 shares were acquired on November 16, 2026 via exercise of stock options from the issuer, with payment made through net exercise.
- Approximate sale date: November 17, 2026, through broker UBS Financial Services, Inc., located at 11 Madison Ave, 4th Floor, New York, NY 10010.
- Prior sales: Murphy sold 4,147 shares of common stock on October 14, 2026, generating gross proceeds of $3,204,379.85, as reported in the past three months section of the filing.
- 10b5-1 plan: The filing indicates a Rule 10b5-1 plan adoption date of May 7, 2026.
- Shares outstanding: The filing states 101,630,713 shares of Regeneron common stock were outstanding at the time of the notice.
Murphy's Proposed Regeneron Share Sale Under Rule 144
According to the Form 144 filed with the U.S. Securities and Exchange Commission on November 17, 2026, Andrew J. Murphy, identified as an officer of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), intends to sell 5,011 shares of the company's common stock. The filing lists the aggregate market value of the proposed sale at $4,773,278.16. The shares are to be sold on Nasdaq through UBS Financial Services, Inc.
The filing discloses that the 5,011 shares were acquired on November 16, 2026, through the exercise of stock options granted by the issuer, with payment described as a net exercise. The notice was signed by UBS Financial Services Inc. as attorney-in-fact for Andrew Murphy. The filing also notes that Murphy adopted a written trading plan under Rule 10b5-1 on May 7, 2026, and that the representation regarding the absence of undisclosed material adverse information is made as of that plan adoption date.
In the section covering securities sold during the past three months, the filing reports that Murphy sold 4,147 shares of Regeneron common stock on October 14, 2026, for gross proceeds of $3,204,379.85. The company's address is listed as 777 Old Saw Mill River Road, Tarrytown, New York 10591, with SEC File Number 000-19034.
What Was Disclosed
Regeneron Pharmaceuticals officer Andrew J. Murphy filed a Form 144 notice proposing the sale of 5,011 shares of common stock valued at $4,773,278.16, acquired via stock option exercise on November 16, 2026, under a Rule 10b5-1 plan adopted May 7, 2026.




Please wait processing your request...